301096 百诚医药
已收盘 07-01 15:00:00
资讯
新帖
简况
百诚医药：公司目前暂未布局青蒿素相关原材料或产品
证券之星 · 06-30 11:33
百诚医药：公司目前暂未布局青蒿素相关原材料或产品
百诚医药：决定终止筹划控制权变更事项
证券之星 · 06-30 11:33
百诚医药：决定终止筹划控制权变更事项
每周股票复盘：百诚医药（301096）2026年推限制性股票激励计划
证券之星 · 06-21
每周股票复盘：百诚医药（301096）2026年推限制性股票激励计划
百诚医药涨7.23%，东吴证券一个月前给出“买入”评级
证券之星 · 06-04
百诚医药涨7.23%，东吴证券一个月前给出“买入”评级
百诚医药（301096）披露2026年限制性股票激励计划（草案），6月2日股价下跌3.51%
证券之星 · 06-02
百诚医药（301096）披露2026年限制性股票激励计划（草案），6月2日股价下跌3.51%
开盘20CM跌停！CRO龙头百诚医药易主告吹，逾1万股民受波及
21世纪经济报道 · 06-01
开盘20CM跌停！CRO龙头百诚医药易主告吹，逾1万股民受波及
医保局发布医保目录调整方案；内蒙古检查售卖集采药违规药店
21世纪经济报道 · 06-01
医保局发布医保目录调整方案；内蒙古检查售卖集采药违规药店
百诚医药宣布终止控股权变更计划，6月1日复牌
美股速递 · 05-31
百诚医药宣布终止控股权变更计划，6月1日复牌
百诚医药最新公告：终止筹划控制权变更事项股票复牌
证券之星 · 05-31
百诚医药最新公告：终止筹划控制权变更事项股票复牌
百诚医药(301096.SZ)：相关各方正在积极推进公司控制权变更事项 继续停牌
智通财经 · 05-26
百诚医药(301096.SZ)：相关各方正在积极推进公司控制权变更事项 继续停牌
连续两年亏损、长期处于破发状态，百诚医药谋划易主
蓝鲸财经 · 05-26
连续两年亏损、长期处于破发状态，百诚医药谋划易主
百诚医药宣布自5月25日起停牌 因控制权或生变
美股速递 · 05-24
百诚医药宣布自5月25日起停牌 因控制权或生变
百诚医药最新公告：筹划控制权变更事项股票停牌
证券之星 · 05-24
百诚医药最新公告：筹划控制权变更事项股票停牌
百诚医药（301096）披露2025年年度股东会决议公告，5月18日股价下跌0.63%
证券之星 · 05-18
百诚医药（301096）披露2025年年度股东会决议公告，5月18日股价下跌0.63%
百诚医药涨5.52%，东吴证券一周前给出“买入”评级
证券之星 · 05-11
百诚医药涨5.52%，东吴证券一周前给出“买入”评级
股市必读：百诚医药年报 - 第四季度单季净利润同比增长50.35%
证券之星 · 04-27
股市必读：百诚医药年报 - 第四季度单季净利润同比增长50.35%
百诚医药（301096）2026年一季报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 04-25
百诚医药（301096）2026年一季报简析：营收净利润同比双双增长，盈利能力上升
图解百诚医药年报：第四季度单季净利润同比增长50.35%
证券之星 · 04-24
图解百诚医药年报：第四季度单季净利润同比增长50.35%
百诚医药（301096）披露2025年度利润分配方案：拟不派息不送股不转增，4月23日股价下跌0.83%
证券之星 · 04-23
百诚医药（301096）披露2025年度利润分配方案：拟不派息不送股不转增，4月23日股价下跌0.83%
股市必读：4月17日百诚医药发生1笔大宗交易 成交金额720.77万元
证券之星 · 04-20
股市必读：4月17日百诚医药发生1笔大宗交易 成交金额720.77万元
加载更多
公司概况
公司名称：
杭州百诚医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2021-12-20
主营业务：
杭州百诚医药科技股份有限公司的主营业务是为各类制药企业、医药研发投资企业提供医药技术受托研发服务（CRO业务）、研发技术成果转化服务、定制研发生产服务（CDMO）。公司的主要产品是药学研究、临床试验、注册申报、研发技术成果转化、定制研发生产服务（CDMO）、自主创新药物研发、受托创新药物研发。公司先后获得“国家高新技术企业”“省级重点企业研究院”“省级技术中心”等荣誉。
发行价格：
79.60
{"stockData":{"symbol":"301096","market":"SZ","secType":"STK","nameCN":"百诚医药","latestPrice":57.66,"timestamp":1782889395000,"preClose":57.19,"halted":0,"volume":3763544,"delay":0,"changeRate":0.0082,"floatShares":83090000,"shares":109000000,"eps":-0.4705,"marketStatus":"已收盘","change":0.47,"latestTime":"07-01 15:00:00","open":57.2,"high":58.21,"low":54.8,"amount":213000000,"amplitude":0.0596,"askPrice":57.67,"askSize":7,"bidPrice":57.66,"bidSize":28,"shortable":0,"etf":0,"ttmEps":-0.4705,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782955800000},"marketStatusCode":5,"adr":0,"adjPreClose":57.19,"symbolType":"stock","openAndCloseTimeList":[[1782869400000,1782876600000],[1782882000000,1782889200000]],"highLimit":62.91,"lowLimit":51.47,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":109228284,"isCdr":false,"pbRate":2.5,"roa":"--","roe":"0.51%","epsLYR":-0.83,"committee":0.496774,"marketValue":6298000000,"turnoverRate":0.0453,"status":0,"floatMarketCap":4791000000},"requestUrl":"/m/hq/s/301096","defaultTab":"news","newsList":[{"id":"2647813355","title":"百诚医药：公司目前暂未布局青蒿素相关原材料或产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2647813355","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647813355?lang=zh_cn&edition=full","pubTime":"2026-06-30 11:33","pubTimestamp":1782790436,"startTime":"0","endTime":"0","summary":"证券之星消息，百诚医药(301096)06月29日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，公司有青蒿素相关产原材料或产品吗？百诚医药回复：尊敬的投资者您好，公司目前暂未布局青蒿素相关原材料或产品，感谢您的关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000017951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647581369","title":"百诚医药：决定终止筹划控制权变更事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2647581369","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647581369?lang=zh_cn&edition=full","pubTime":"2026-06-30 11:33","pubTimestamp":1782790436,"startTime":"0","endTime":"0","summary":"证券之星消息，百诚医药(301096)06月29日在投资者关系平台上答复投资者关心的问题。投资者提问：实控人此前曾增持股份，本次股权转让中，交易方报价溢价约20%-30%，未达到实控人50%左右的预期溢价。请问终止转让，是否是基于对公司后续发展的信心，坚持认可公司更高价值？百诚医药回复：尊敬的投资者您好，相关交易方经慎重考虑、磋商，认真听取各方意见，决定终止筹划控制权变更事项。公司严格按照信息披露的相关规定履行信息披露义务，尚未公开披露交易方报价等信息，请以公司公开披露信息为准。感谢您的关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000017952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645096152","title":"每周股票复盘：百诚医药（301096）2026年推限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2645096152","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645096152?lang=zh_cn&edition=full","pubTime":"2026-06-21 03:13","pubTimestamp":1781982789,"startTime":"0","endTime":"0","summary":"本周关注点来自公司公告汇总：百诚医药审议通过2026年限制性股票激励计划（草案）及相关议案。公司公告汇总杭州百诚医药科技股份有限公司于2026年6月17日召开2026年第一次临时股东会，采用现场与网络投票结合方式，审议通过选举第四届董事会非独立董事、续聘天健会计师事务所、2026年限制性股票激励计划（草案）及其摘要、实施考核管理办法、提请股东会授权董事会办理股权激励相关事宜等议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100001031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640534461","title":"百诚医药涨7.23%，东吴证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2640534461","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640534461?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:46","pubTimestamp":1780562784,"startTime":"0","endTime":"0","summary":"今日百诚医药（301096）涨7.23%，收盘报58.74元。2026年4月29日，东吴证券研究员朱国广,苏丰,邹行健发布了对百诚医药的研报《2025年报&2026一季报点评：26Q1利润超预期，创新管线持续推进》，该研报对百诚医药给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为69.92%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为西部证券的吴天昊。百诚医药（301096）个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400028748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","601555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640911335","title":"百诚医药（301096）披露2026年限制性股票激励计划（草案），6月2日股价下跌3.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640911335","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640911335?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:42","pubTimestamp":1780393356,"startTime":"0","endTime":"0","summary":"截至2026年6月2日收盘，百诚医药报收于56.35元，较前一交易日下跌3.51%，最新总市值为61.55亿元。该股当日开盘58.0元，最高60.41元，最低56.31元，成交额达4.15亿元，换手率为8.56%。近日，杭州百诚医药科技股份有限公司披露《2026年限制性股票激励计划（草案）》。公告显示，本次激励计划拟采用第二类限制性股票形式，股票来源为定向发行A股普通股，拟授予不超过500.00万股，占公司总股本的4.58%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200034437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640798290","title":"开盘20CM跌停！CRO龙头百诚医药易主告吹，逾1万股民受波及","url":"https://stock-news.laohu8.com/highlight/detail?id=2640798290","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640798290?lang=zh_cn&edition=full","pubTime":"2026-06-01 09:47","pubTimestamp":1780278420,"startTime":"0","endTime":"0","summary":"公告一出，引发市场对这家CRO龙头易主的种种猜想。财务数据显示，2025年，百诚医药实现营业总收入6.78亿元，同比下降15.45%；归母净利润则连续第二年出现亏损，亏损额从上年同期的5274.28万元扩大至9039.55万元。公司2026年一季度实现净利润1281.25万元，成功扭亏为盈。公司称，业绩改善主要得益于仿制药CRO/CDMO业务逐步企稳、集采中标品种商业化稳步开展以及降本增效措施取得成效。Wind数据显示，百诚医药股东户数月1.12万名。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2026-06-01/doc-inhzwist5284387.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-06-01/doc-inhzwist5284387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640981365","title":"医保局发布医保目录调整方案；内蒙古检查售卖集采药违规药店","url":"https://stock-news.laohu8.com/highlight/detail?id=2640981365","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640981365?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:01","pubTimestamp":1780272073,"startTime":"0","endTime":"0","summary":"药械审批国家医保局发布2026年国家医保目录调整工作方案5月31日，国家医保局发布《2026年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整工作方案》《2026年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整申报指南》《谈判药品续约规则》以及《非独家药品竞价规则》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606013755285483.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606013755285483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["300562","BK0188","BK0187","BK0216","BK0070","301096","600196","IPOS","301263","BK0185","BK0196","BK0251","BK0114","600513","BK0060","BK0028","BK0250","BK0012","BK0096","BK0109","600521","BK0201","BK0239","BK0183","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125892899","title":"百诚医药宣布终止控股权变更计划，6月1日复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=1125892899","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125892899?lang=zh_cn&edition=full","pubTime":"2026-05-31 16:32","pubTimestamp":1780216363,"startTime":"0","endTime":"0","summary":"杭州百诚医药科技股份有限公司发布公告，其筹划中的控制权变更事项已决定终止。公司股票将于6月1日开市起恢复交易。\n此前，公司因筹划相关事项而申请股票停牌。经过与交易对方的审慎沟通与协商，双方未能就本次交易的关键条款达成一致意见。基于此，为切实维护公司及全体股东利益，经审慎研究，公司决定终止本次控制权变更事项。\n该事项的终止不会对公司正常生产经营产生重大不利影响。公司目前经营状况稳定，各项业务有序开展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639600387","title":"百诚医药最新公告：终止筹划控制权变更事项股票复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2639600387","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639600387?lang=zh_cn&edition=full","pubTime":"2026-05-31 15:40","pubTimestamp":1780213206,"startTime":"0","endTime":"0","summary":"百诚医药(301096.SZ)公告称，公司在停牌期间与交易对方就控制权变更事项进行充分探讨，但因涉及事项较多，经慎重考虑，决定终止筹划此次控制权变更。公司股票将于2026年6月1日开市起复牌，终止该事项不会对公司生产经营造成不利影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100003515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638902175","title":"百诚医药(301096.SZ)：相关各方正在积极推进公司控制权变更事项 继续停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2638902175","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638902175?lang=zh_cn&edition=full","pubTime":"2026-05-26 17:28","pubTimestamp":1779787738,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百诚医药(301096.SZ)发布公告，公司控股股东、实际控制人邵春能先生、楼金芳女士及其一致行动人正在筹划涉及公司控制权变更的重大事项。截止本公告日，相关各方正在积极推进上述事项的工作，公司预计无法在2026年5月27日(星期三)开市起复牌。根据深圳证券交易所的相关规定，经公司向深圳证券交易所申请，公司股票将于2026年5月27日(星期三)开市起继续停牌，预计继续停牌时间不超过3个交易日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638567060","title":"连续两年亏损、长期处于破发状态，百诚医药谋划易主","url":"https://stock-news.laohu8.com/highlight/detail?id=2638567060","media":"蓝鲸财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638567060?lang=zh_cn&edition=full","pubTime":"2026-05-26 12:08","pubTimestamp":1779768507,"startTime":"0","endTime":"0","summary":"据百诚医药2026年一季报显示，邵春能、楼金芳夫妻二人持股比例分别为18.55%和13.22%，据此合计持股约31.77%。2021年底，百诚医药登陆深交所创业板，不过，公司长期处于破发状态，发行价为79.60元，而停牌前股价为64.60元。对于亏损的原因，百诚医药在2024年年报中解释，报告期内营业收入变动原因主要系公司仿制药业务受集采、 MAH 制度等政策的影响，营业收入下降。今年以来，CRO行业掀起了一轮整合与易主潮。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1779768465065578325","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192233326","title":"百诚医药宣布自5月25日起停牌 因控制权或生变","url":"https://stock-news.laohu8.com/highlight/detail?id=1192233326","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192233326?lang=zh_cn&edition=full","pubTime":"2026-05-24 15:43","pubTimestamp":1779608591,"startTime":"0","endTime":"0","summary":"杭州百诚医药科技股份有限公司发布公告称，公司股票自5月25日开市起停牌，以待潜在控制权变更事项的推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637471370","title":"百诚医药最新公告：筹划控制权变更事项股票停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2637471370","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637471370?lang=zh_cn&edition=full","pubTime":"2026-05-24 15:39","pubTimestamp":1779608375,"startTime":"0","endTime":"0","summary":"百诚医药(301096.SZ)公告称，公司控股股东、实际控制人邵春能、楼金芳及其一致行动人正在筹划涉及公司控制权变更的重大事项，可能导致公司控制权发生变更。为保证公平信息披露，避免股价异常波动，公司股票自2026年5月25日开市起停牌，预计停牌时间不超过2个交易日。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400004316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636021666","title":"百诚医药（301096）披露2025年年度股东会决议公告，5月18日股价下跌0.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636021666","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636021666?lang=zh_cn&edition=full","pubTime":"2026-05-18 17:44","pubTimestamp":1779097459,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，百诚医药报收于63.28元，较前一交易日下跌0.63%，最新总市值为69.12亿元。该股当日开盘64.05元，最高64.45元，最低62.9元，成交额达1.56亿元，换手率为2.96%。近日，杭州百诚医药科技股份有限公司发布《2025年年度股东会决议公告》。会议出席股东及代理人共54人，代表有表决权股份42,365,635股，占公司有表决权股份总数的39.0643%。关联股东对董事薪酬方案议案回避表决。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800028235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634840943","title":"百诚医药涨5.52%，东吴证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2634840943","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634840943?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:38","pubTimestamp":1778488730,"startTime":"0","endTime":"0","summary":"今日百诚医药（301096）涨5.52%，收盘报63.82元。2026年4月29日，东吴证券研究员朱国广,苏丰,邹行健发布了对百诚医药的研报《2025年报&2026一季报点评：26Q1利润超预期，创新管线持续推进》，该研报对百诚医药给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为69.92%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为西部证券的吴天昊。百诚医药（301096）个股概况：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100022215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","601555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630486335","title":"股市必读：百诚医药年报 - 第四季度单季净利润同比增长50.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630486335","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630486335?lang=zh_cn&edition=full","pubTime":"2026-04-27 02:17","pubTimestamp":1777227428,"startTime":"0","endTime":"0","summary":"股本股东变化股东户数变动近日百诚医药披露，截至2026年3月31日公司股东户数为1.12万户，较12月31日增加106.0户，增幅为0.95%。2025年内部控制审计报告天健会计师事务所对杭州百诚医药科技股份有限公司截至2025年12月31日的财务报告内部控制有效性进行了审计。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700005086.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630873953","title":"百诚医药（301096）2026年一季报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2630873953","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630873953?lang=zh_cn&edition=full","pubTime":"2026-04-25 06:35","pubTimestamp":1777070134,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期百诚医药发布2026年一季报。截至本报告期末，公司营业总收入1.6亿元，同比上升24.65%，归母净利润1281.25万元，同比上升148.91%。本报告期百诚医药盈利能力上升，毛利率同比增幅21.35%，净利率同比增幅139.24%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500021918.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629514028","title":"图解百诚医药年报：第四季度单季净利润同比增长50.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629514028","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629514028?lang=zh_cn&edition=full","pubTime":"2026-04-24 01:04","pubTimestamp":1776963861,"startTime":"0","endTime":"0","summary":"证券之星消息，百诚医药2025年年报显示，当年度公司主营收入6.78亿元，同比下降15.45%；归母净利润-9039.55万元，同比下降71.39%；扣非净利润-1.03亿元，同比下降41.96%；其中2025年第四季度，公司单季度主营收入1.68亿元，同比上升108.97%；单季度归母净利润-9651.97万元，同比上升50.35%；单季度扣非净利润-8918.95万元，同比上升54.87%；负债率32.48%，投资收益-1179.68万元，财务费用1803.26万元，毛利率39.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400002669.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629971858","title":"百诚医药（301096）披露2025年度利润分配方案：拟不派息不送股不转增，4月23日股价下跌0.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629971858","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629971858?lang=zh_cn&edition=full","pubTime":"2026-04-23 22:22","pubTimestamp":1776954144,"startTime":"0","endTime":"0","summary":"截至2026年4月23日收盘，百诚医药报收于57.19元，较前一交易日下跌0.83%，最新总市值为62.47亿元。近日，杭州百诚医药科技股份有限公司披露《关于公司2025年度利润分配方案的公告》。公告显示，公司于2026年4月23日召开第四届董事会第十次会议，审议通过《关于公司2025年度利润分配方案的议案》，该议案尚需提交2025年年度股东会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300062526.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628793401","title":"股市必读：4月17日百诚医药发生1笔大宗交易 成交金额720.77万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628793401","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628793401?lang=zh_cn&edition=full","pubTime":"2026-04-20 03:09","pubTimestamp":1776625748,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，百诚医药报收于57.94元，下跌0.43%，换手率3.35%，成交量2.78万手，成交额1.61亿元。当日关注点来自交易信息汇总：4月17日主力资金净流出1241.2万元，游资资金净流入1408.53万元。大宗交易4月17日百诚医药发生1笔大宗交易，成交金额720.77万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000001112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782944034107,"stockEarnings":[{"period":"1week","weight":0.0838},{"period":"1month","weight":-0.0127},{"period":"3month","weight":0.0859},{"period":"6month","weight":0.0091},{"period":"1year","weight":0.2836},{"period":"ytd","weight":0.0091}],"compareEarnings":[{"period":"1week","weight":0.0004},{"period":"1month","weight":0.0135},{"period":"3month","weight":0.0493},{"period":"6month","weight":0.0362},{"period":"1year","weight":0.1893},{"period":"ytd","weight":0.0362}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"杭州百诚医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"11216人(较上一季度增加0.95%)","perCapita":"7408股","listingDate":"2021-12-20","address":"浙江省杭州市临平区临平街道绿洲路159号","registeredCapital":"10922万元","survey":" 杭州百诚医药科技股份有限公司的主营业务是为各类制药企业、医药研发投资企业提供医药技术受托研发服务（CRO业务）、研发技术成果转化服务、定制研发生产服务（CDMO）。公司的主要产品是药学研究、临床试验、注册申报、研发技术成果转化、定制研发生产服务（CDMO）、自主创新药物研发、受托创新药物研发。公司先后获得“国家高新技术企业”“省级重点企业研究院”“省级技术中心”等荣誉。","listedPrice":79.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百诚医药(301096)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百诚医药(301096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百诚医药,301096,百诚医药股票,百诚医药股票老虎,百诚医药股票老虎国际,百诚医药行情,百诚医药股票行情,百诚医药股价,百诚医药股市,百诚医药股票价格,百诚医药股票交易,百诚医药股票购买,百诚医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百诚医药(301096)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百诚医药(301096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}